SCHEMBL1158779

SCHEMBL1158779

CC[C@H](C)Nc1nc(Nc2ccccn2)cc2cc[nH]c(=O)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TYK2 P29597 2/20 0.38
ZAP70 P43403 3/20 0.38
JAK2 O60674 4/20 0.37
GRM5 P41594 2/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
CDC25B P30305 1/20 0.37
CASP6 P55212 1/20 0.37
RCE1 Q9Y256 1/20 0.37
ELANE P08246 1/20 0.36
FER P16591 1/20 0.36
LYN P07948 2/20 0.35
SYK P43405 1/20 0.35
SRC P12931 1/20 0.35
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158516 1.00 MEN1 (0.38) MEN1NPC1RAB9AKMT2ATYK2
SCHEMBL1158368 0.91 GRM5 (0.39) TYK2ZAP70JAK2GRM5APAF1
SCHEMBL1158263 0.91 GRM5 (0.39) TYK2ZAP70JAK2GRM5APAF1
SCHEMBL1158763 0.91 GRM5 (0.39) TYK2ZAP70JAK2GRM5APAF1
SCHEMBL1158539 0.91 ZAP70 (0.37) NPC1RAB9ATYK2ZAP70JAK2
SCHEMBL1158401 0.89 TRPM8 (0.41) TYK2ZAP70JAK2GRM5TRPM8
SCHEMBL1158115 0.87 JAK2 (0.43) TYK2ZAP70JAK2GRM5TRPM8
SCHEMBL1158202 0.87 FER (0.39) TYK2ZAP70JAK2FERSYK
SCHEMBL1158737 0.87 FER (0.39) TYK2ZAP70JAK2FERSYK
SCHEMBL1158433 0.84 ZAP70 (0.40) TYK2ZAP70JAK2GRM5APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN MEN1 4503/4885NPC1 2222/4885RAB9A 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.